Topoisomerase 1 (Top1) is the intercellular target of camptothecins (CPTs). CPT blocks DNA religation in the Top1-DNA complex and induces Top1-attached nick DNA lesions. In this study, we demonstrate that excision repair cross complementing 1 protein-xeroderma pigmentosum group F (ERCC1-XPF) endonuclease and replication protein A (RPA) participate in the repair of Top1-attached nick DNA lesions together with other nucleotide excision repair (NER) factors. ERCC1-XPF shows nuclease activity in the presence of RPA on a 3′-phosphotyrosyl bond nick-containing DNA (Tyr-nick DNA) substrate, which mimics a Top1-attached nick DNA lesion. In addition, ERCC1-XPF and RPA form a DNA/protein complex on the nick DNA substrate in vitro, and co-localize in CPT-treated cells in vivo. Moreover, the DNA repair synthesis of Tyr-nick DNA lesions occurred in the presence of NER factors, including ERCC1-XPF, RPA, DNA polymerase delta, flap endonuclease 1 and DNA ligase 1. Therefore, some of the NER repair machinery might be an alternative repair pathway for Top1-attached nick DNA lesions. Clinically, these data provide insights into the potential of ERCC1 as a biomarker during CPT regimens.
Introduction
Two long strands of a duplex DNA template carrying genomic information must be separated precisely for ubiquitous and essential DNA metabolism reactions, such as transcription, replication, recombination, repair and chromatin remodeling. Because the sizable protein complexes required for DNA metabolism do not rotate freely around the DNA molecule, DNA supercoiling occurs. DNA topoisomerases are essential eukaryotic enzymes that regulate DNA topology by relaxing DNA supercoiling (1, 2) . DNA topoisomerase 1 (Top1) is one of seven DNA topoisomerases encoded by the mammalian genome (3) . Top1 binds to DNA molecules at nicks (single-strand breaks) to stabilize the DNA (4, 5) . An enzymatic reaction then occurs to form a Top1-DNA complex via a covalent bond between the 3′-phosphoryl end of the nicked DNA and a tyrosine residue in the enzyme. This reaction enables swiveling of the nick DNA around the intact strand. The DNA then relaxes, and Top1 religates the nicked DNA by reversing the covalent bond without any requirement for adenosine triphosphate or any energy source.
Camptothecin (CPT) is a human Top1 inhibitor that is effective against a broad spectrum of tumors (1, 6) . Biochemical studies have demonstrated that CPT binds to Top1-DNA complexes at the interface between Top1 and the nicked DNA to form a cleavage complex (7) . Once bound, it inhibits the religation step in the enzymatic reaction specifically, which traps the nick with Top1 attached at the 3′-phosphoryl end and a free 5′-hydroxyl end (the Top1-attached DNA nick complex). The molecular mechanism of CPT is thought to involve the lethal conversion of the Top1-attached DNA nick complex to a double-stranded break by generating a collision between the replication fork and the cleavage complexes during S phase of the cell cycle (8) . Alternatively, it may involve the apoptosis-induced arrest of the transcription elongation step by blocking the nick complexes on transcribed strands (9, 10) .
The solution of the Top1-attached DNA nick complexes that results in the death of cancer cells is not fully understood. When cells are treated with CPT, Top1 in the complexes is degraded via the ubiquitin-26S proteasome pathway (10, 11) . Therefore, it has been suggested that degradation of Top1 in the nick complexes is needed for repair of Top1-cleavage complexes. Human tyrosine-DNA phosphodiesterase 1 (TDP1) catalyzes the hydrolysis of the DNA tyrosyl-phosphodiester bond between the tyrosine residue and the DNA 3′ phosphate group (6, 12) . Because DNA ligase is unable to close the nick containing the 3′-phosphoryl end and 5′-hydroxyl end, cooperation between polynucleotide kinase 3′-phosphatase and DNA ligase is thought to repair the nick (5) .
Data regarding the repair of CPT-induced Top1-attached DNA nick complexes in yeast and humans (13, 14) suggest that structure-specific DNA endonucleases remove the 3′ end of the DNA. Examples include human excision repair cross complementing 1 protein (ERCC1)-xeroderma pigmentosum group F complementing protein (XPF) and its yeast ortholog Rad10-Rad1, which participate in the repair of Top1-attached nick DNA complexes in addition to nucleotide excision repair (NER), homologous recombination repair and interstrand crosslink repair.
The heterodimeric complex ERCC1-XPF is composed of two subunits, ERCC1 and XPF, and it cleaves damaged DNA strands on the 5′ side of the open bubble structure that forms around a lesion during NER (15, 16) . NER removes bulky DNA lesions that block replication and transcription via two pathways: global genome NER (17) and transcription-coupled NER (TC-NER) (18) . ERCC1-XPF plays a role in both NER pathways. The 3′-end of the DNA strand generated by this enzyme undergoes DNA repair synthesis by DNA polymerase, DNA ligase and flap structure-specific endonuclease 1 (FEN1) (19, 20) . When a double-stranded break is induced by DNA damage between two homologous sequences (21), homologous recombination repair uses this structure-specific enzyme to remove the 3′-end unpaired single strands that are generated during the single strand annealing step (22) , leading to the formation of a 3′-flap structure. After removal of the unpaired regions, resynthesis and gap filling steps then occur. ERCC1-XPF is also involved in the repair of the inter-strand cross-link damage that is induced by DNA cross-linking agents (23) . This enzyme complex can release one arm of a cross-link with a Y-form structure that resembles stalled DNA replication. As such, ERCC1 or XPF-defective cells are hypersensitive to DNA cross-linking agents (24) .
During the repair of Top1-attached DNA nick complexes, the structure-specific DNA endonuclease ERCC1-XPF is thought to remove oligonucleotides that contain a tyrosyl-phosphodiester bond on their 3′ end (13, 14) . Here, ERCC1-XPF might function as a TDP1 "backup enzyme" in an alternative repair pathway. However, it is currently unknown whether this enzyme cleaves the 3′-phosphotyrosyl bonds on single-stranded DNA (ssDNA) in nicks after the degradation of Top1. DNA structures that contain a 3′-phosphotyrosyl bond do not directly form bubble structures, 3′-flap structures and Y-form structures, which can all be cleaved by ERCC1-XPF. The enzymes that participate in the DNA repair synthesis process after the cleavage of the 3′-phosphotyrosyl bonds by ERCC1-XPF are also yet to be elucidated.
In the current study, we prepared recombinant ERCC1-XPF enzymes in Escherichia coli and chemically synthesized oligonucleotides that contain 3′-phosphotyrosyl bonds to mimic the lesions that are repaired by the Top1-attached DNA nick complex. Data demonstrated that ERCC1-XPF exerts nuclease activity on 3′-phosphotyrosyl DNA that has formed Y-shaped structures. Furthermore, replication protein A (RPA) participates in the nuclease activity of ERCC1-XPF during this repair process. Finally, reconstitution of the repair reaction using purified human proteins provided insights into the DNA repair mechanisms of CPT induced Top1-DNA complexes in tumor cells.
Materials and methods

Protein purification
The pCOLADuet™-1 (Novagen, Madison, WI)-ERCC1-XPF vector expressed XPF with an N-terminal FLAG tag and 6×His-tag, and ERCC1 with a C-terminal FLAG tag and 6×His-tag. Escherichia coli Rosseta™2 (DE3) cells (Novagen) were transformed with pCOLADuet-1-ERCC1-XPF and then induced with 0.5 mM isopropyl-1-thio-ß-D-galactopyranoside at 12°C for 40 h. Cells were lysed by sonication in buffer A [20 mM Tris-HCl pH 8.0, 0.5 M KCl, 2 mM MgCl 2 , 10% glycerol, 0.1 mM phenylmethylsulfonyl fluoride, and protease inhibitor (Sigma, St Louis, MO)] containing 20 mM imidazole. The lysates were centrifuged at 15 000g for 30 min. Clarified supernatant was loaded on a diethylaminoethyl sepharose column, and the flow-through was loaded on a nickel-agarose column, washed with buffer A containing 20 mM imidazole, and ERCC1-XPF was then eluted in buffer A containing 250 mM imidazole. The eluted fractions and anti-DYKDDDDK beads (Wako Pure Chemical, Osaka, Japan) were incubated at 4°C for 2 h, and eluted in buffer B [20 mM Tris-HCl (pH 8.0), 0.5 M KCl, 2 mM MgCl 2 , 10% glycerol, 0.1 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, 0.01% Triton X-100 and 0.2 mg/ml DYKDDDDK peptide]. The purified fractions were stored at −80°C. For biochemical assays, fresh dilutions were made from 1 pmol/μl purified ERCC1-XPF complex stock using buffer B.
The pET-16b™ (Novagen)-FEN1 vector contained FEN1 with a C-terminal 6×His-tag. Escherichia coli BL™ 21 cells (Novagen) were transformed with pET-16b-FEN1 and induced with 0.1 mM isopropyl-1-thio-ß-D-galactopyranoside at 12°C for 40 h. Cells were then lysed by sonication in buffer A. The lysates were centrifuged at 15 000g for 30 min. Clarified supernatant was loaded on a nickel-agarose column and washed with buffer C (20 mM Tris-HCl pH 8.0, 2 mM MgCl 2 , 10% glycerol, 0.1 mM phenylmethylsulfonyl fluoride and protease inhibitor) containing 20 mM imidazole and 0.5 M KCl. FEN1 was then eluted in buffer B containing 250 mM imidazole and 50 mM KCl. The eluted fractions were loaded on a HiTrap Heparin HP column (GE Healthcare Life Science), and the column was eluted with a gradient of 50-1000 mM KCl in buffer C. The peak fractions were stored at −80°C until use.
The pET-101™ (Novagen)-DNA ligase 1 (LIG1) vector had LIG1 with C-terminal FLAG-, V5-, and 6×His-tags. cells (Novagen) were transformed with pET-101-LIG1 and then induced using 0.1 mM isopropyl-1-thio-ß-D-galactopyranoside at 16°C for 18 h. Cells were lysed by sonication in buffer A containing 20 mM imidazole. The lysates were centrifuged at 15 000g for 30 min. Clarified supernatant was loaded on a diethylaminoethyl sepharose column, and the flow-through was loaded on a nickel-agarose column and then washed with buffer A containing 20 mM imidazole. Finally, LIG1 was eluted using buffer A containing 250 mM imidazole. The eluted fractions were incubated with anti-DYKDDDDK beads at 4°C for 2 h, and eluted in buffer B. Purified fractions were stored at −80°C. RPA and POLD were purified and stored at −80°C, as described previously (25) .
Preparation of DNA substrates
The preparation of 3′-Y-18-nt oligonucleotides was described previously (26) . high-performance liquid chromatography-purified oligonucleotides were 5′-labeled with γ− 32 P]-adenosine triphosphate and T4 polynucleotide kinase. Unincorporated radioactive nucleotides were removed using a G-25 spin column (GE Healthcare Life Science). 
Nuclease assays
Nuclease assays were performed as described previously (16, 23) . Briefly, reaction mixtures (10 μl) contained 250 fmol of 32 P-labeled substrate, 250 fmol ERCC1-XPF and 250 fmol RPA in buffer D (50 mM Tris-HCl pH 8.0, 0.1 mg/ml bovine serum albumin and 5 mM ß-mercapthoethanol) containing 0.5 mM MnCl 2. The reaction mixture was incubated at 30°C for 90 min, and reactions were terminated by the addition of denaturing gel loading buffer (10 μl; 96% formamide, 10 mM ethylenediaminetetraacetic acid, 0.1% xylene cyanol and 0.1% bromophenol blue). The reaction mixture was subsequently heated at 95°C for 3 min, and the products were analyzed on denaturing 14% polyacrylamide gels using an FLA 7000 image analyzer (GE Healthcare).
Reconstruction assays
Assays were performed as described previously (27) . Reaction mixtures (10 μl) contained 250 fmol of DNA, 1 pmol of ERCC1-XPF, 1 pmol of RPA and 1 pmol of POLD in buffer E (40 mM HEPES-KOH pH 7.8, 7 mM MgCl 2 , 0.5 mM MnCl 2 , 1 mM dithiothreitol, 0.5 mM ethylenediaminetetraacetic acid, 2 mM adenosine triphosphate, 20 μM deoxynucleoside triphosphate mixture and 0.5 mg/ml bovine serum albumin). The reaction mixture was incubated at 37°C for 90 min. Then, 1 pmol of FEN1 and 1 pmol of LIG1 were added, and the reaction was incubated at 37°C for 30 min; it was then terminated by the addition of gel loading buffer (10 μl). The mixture was subsequently heated at 95°C for 3 min, and the products were analyzed on denaturing 20% polyacrylamide gels.
DNA binding assays
The standard reaction mixtures (40 μl) contained 250 fmol of DNA, 2 pmol of ERCC1-XPF and 2 pmol of RPA in buffer C (50 mM Tris-HCl pH 8.0, 0.1 mg/ml bovine serum albumin and 5 mM ß-mercapthoethanol) containing 2 mM CaCl 2 . The reaction mixture was incubated at 30°C for 60 min, and 4 μl of binding loading buffer was added (50% glycerol, 0.1% xylene cyanol and 0.1% bromophenol blue). The reaction mixture (8 μl) was analyzed on 8% native polyacrylamide gels run in 0.5× Tris-Borate-EDTA buffer for 2 h at 250 V and room temperature. The products were analyzed using an FLA 7000 image analyzer. To analyze the ERCC1-XPF-DNA complex formation, the standard reaction mixture was incubated at 30°C for 60 min. Then, 10 μL of anti-DYKDDDDK beads were added, and the mixtures were incubated at 4°C for 30 min. After the reaction mixtures were centrifuged, the supernatants were analyzed on 8% native polyacrylamide gels.
Cell line and cell culture
HeLa S3 cells and HEK293 cells stably expressing C-terminally FLAG-V5-6xHis-tagged ERCC1 were used in this study. The HeLa S3 cells were kindly gifted by Dr Takasi Yagi (Osaka Prefecture University). HEK293 cells were purchased from Invitrogen. HEK293 cells stably expressing C-terminally FLAG-V5-6xHis-tagged ERCC1 were established using a pcDNA5/FRT/ V5-His TOPO TA Expression Kit (Invitrogen) according to the manufacturer's instructions. Cells were cultured in Dulbecco's modified Eagle medium (Wako) containing 15% fetal bovine serum (HyClone Laboratories, Logan, UT), 100 units penicillin and 100 μg/ml streptomycin, and were incubated at 37°C in a humidified 5% CO 2 incubator. Once resuscitated, cell lines were routinely authenticated through cell morphology monitoring and absence of microbial contamination was confirmed. Cell lines were stored according to the manufacturer's instructions.
Immunofluorescence assays
Cells were cultured on 15 mm micro-cover glasses to 30-50% confluence in Dulbecco's modified Eagle medium (Wako) containing 15% fetal bovine serum (HyClone Laboratories, Logan, UT), 100 units penicillin and 100 μg/ ml streptomycin, and were incubated at 37°C in a humidified 5% CO 2 incubator. CPT (Wako) was dissolved in dimethyl sulfoxide (Wako). CPT-treated cells were washed three times with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde in PBS for 30 min. The fixed cells were washed three times with PBS and were then incubated for 30 min in PBS containing 0.1% Triton X-100 (PBST). The samples were blocked with 5% Blocking One buffer (Nacalai, Kyoto, Japan) in PBST for 30 min and incubated for 1 h at room temperature with anti-XPF (H-300; Santa Cruz Biotechnology, 1:400), anti-DDDDK-tag pAb (MBL, Nagoya, Japan) and anti-RPA2 (9H8; Abcam, 1:400) antibodies. The cells were then washed with PBST and incubated for 1 h at room temperature with Alexa Fluor 488-or 568-conjugated mouse or rabbit IgG antibodies (Molecular Probes, 1:400), respectively. The samples were examined using a Nikon Ti Eclipse inverted microscope, and confocal images were deconvoluted and fluorescent intensities were determined using NIS Elements Advanced Research software (Nikon, Tokyo, Japan).
Results
ERCC1-XPF possesses structure-specific nuclease activity for the repair of Top1 damage
Recombinant ERCC1-XPF was purified as a complex of its subunits ( Figure 1A ). The complex produced in E. coli was functional, and the enzyme possessed structural nuclease activity toward stem loops (16, 23) and splayed arms (Supplementary Figure S1A and B, available at Carcinogenesis Online).
To assess the ability of ERCC1-XPF to cleave near junctions containing 3′-phosphotyrosyl oligonucleotide, an 18mer oligonucleotide containing a non-phosphotyrosyl oligonucleotide ( Figure 1B, upper panel) or a 3′-phosphotyrosyl oligonucleotide ( Figure 1C, upper panel) was synthesized. Each strand was 5′-labeled with 32 P, and annealed to a complementary oligonucleotide to form Y structures. The enzyme was then incubated at 30°C for 90 min. ERCC1-XPF cleaved near the junction containing the non-phosphotyrosyl ( Figure 1B, right panel) or 3′-phosphotyrosyl oligonucleotide ( Figure 1C, right panel) . The main cleavage site was located two phosphodiester bonds away from the junction, and the cleavage released a labeled 10mer ( Figures 1B and  C, lane 5) . This suggests that the nuclease activity of ERCC1-XPF was unaffected by the presence of 3′-phosphotyrosyl bonds on the ssDNA.
Next, to determine whether the ERCC1-XPF nuclease activity was structure-specific, we assessed whether ERCC1-XPF could cleave nicked DNA structure substrates (Figure 2A and 2B, upper panel). Because the ubiquitin-26S proteasome cleaves a Top1 complex, nicked substrates containing 3′-phosphotyrosyl bonds are more likely substrates for DNA repair (5,6). However, ERCC1-XPF did not possess significant nuclease activity on nick substrates containing either non-phosphotyrosyl (Figure 2A ) or 3′-phosphotyrosyl bonds ( Figure 2B ). When 5′-ss-overhang substrates (Supplementary Figure S2A and Figure S2C and D, upper panel, available at Carcinogenesis Online) were used, ERCC1-XPF could cleave ss regions on DNA, regardless of the presence or absence of 3′-phosphotyrosyl bonds. The main cleavage sites in the 5′-overhang substrates or 3′-flap substrates were 5′-phosphodiester bonds away from the 3′-end of the junction, which released a labeled 13mer (Supplementary Figure S2A and B, available at Carcinogenesis Online) or 10mer (Supplementary Figure S2C and D, available at Carcinogenesis Online), respectively. These results suggest that ERCC1-XPF possesses structure-specific nuclease activity during DNA repair by removing 3′-phosphotyrosyl bonds in Top1-attached DNA nick complexes that have specific structures.
In addition, ERCC1-XPF could not cleave ssDNA and dsDNA substrates containing non-phosphotyrosyl (Supplementary Figure S3A and C, available at Carcinogenesis Online) or 3′-phosphotyrosyl oligonucleotides (Supplementary Figure S3B and D, available at Carcinogenesis Online).
RPA stimulates ERCC1-XPF nuclease activity during the repair of Top1 damage
Although nicked substrates containing 3′-phosphotyrosyl bonds are more likely substrates for the repair of Top1-attached nick DNA complexes, the nuclease activity of ERCC1-XPF required structure specific substrates. To remove 3′-phosphotyrosyl bonds, ERCC1-XPF might require additional proteins to function prior to its intrinsic nuclease activity. Therefore, we assessed whether RPA stimulates the nuclease activity of ERCC1-XPF toward nicked substrates that contained 3′-phosphotyrosyl bonds. RPA forms a complex with ERCC1-XPF and stimulates ERCC1-XPF nuclease activity on 5′-ss-overhang substrates (28) . Therefore, we added RPA to the current experimental system. In the presence of low concentrations of RPA, ERCC1-XPF could not cleave nicked substrates that contained non-phosphotyrosyl or 3′-phosphotyrosyl bonds. However, RPA stimulated ERCC1-XPF activity toward nicked substrates containing 3′-phosphotyrosyl bonds, but not non-phosphotyrosyl bonds, in a dose-dependent manner, resulting in the release of a labeled 9mer and 8mer ( Figures 2C and 2D, lanes 4-5) .
To test whether the stimulatory effect was specific to RPA, similar assays were performed using E. coli single-stranded binding proteins (SSB). SSB did not affect ERCC1-XPF nuclease activity toward these substrates ( Figures 2E and F) . Therefore, these results suggest that RPA stimulation is required for ERCC1-XPF nuclease activity toward nick substrates containing unstructured 3′-phosphotyrosyl bonds. RPA also stimulated ERCC1-XPF nuclease activity (3′ to 5′ exonuclease activity) toward dsDNA substrates in an RPA concentration-dependent manner (Supplementary Figure S4A , available at Carcinogenesis Online), whereas SSB did not (Supplementary Figure S4B , available at Carcinogenesis Online). Thus, SSB was likely to inhibit the nuclease activity (28).
ERCC1-XPF and RPA bind to Top1-damaged DNA
As reported previously (28) , the stimulatory effect of RPA on ERCC1-XPF nuclease activity suggests that RPA facilitates the positioning of this nuclease on 5′-overhang-containing DNA substrates. Therefore, we hypothesized that ERCC1-XPF-RPA complex formation occurs on nicked substrates that contain 3′ phosphotyrosyl bonds. To test this hypothesis, the binding of each protein to DNA substrates was assessed in DNA binding assays under non-cleavage experimental conditions that inhibited nuclease activity using CaCl 2 . ERCC1-XPF ( Figure 3A) or RPA ( Figure 3B ) formed protein/DNA complexes with nicked substrates that contain 3′-phosphotyrosyl bonds in a protein concentration-dependent manner. Although ERCC1-XPF or RPA also formed the protein/dsDNA or protein/nicked DNA complexes (Supplementary Figure S5 , available at Carcinogenesis Online), they had a preference toward nicked DNA rather than dsDNA (Supplementary Figure S5C and D versus Supplementary Figure S5A and B, available at Carcinogenesis Online, respectively). It is worth noting that RPA/nicked DNA complexes were more stable than were ERCC1-XPF DNA complexes ( Figure 3B and Supplementary Figure S5D , available at Carcinogenesis Online). In the presence of ERCC1-XPF and RPA, a super-shifted band was observed ( Figure 3C, lane 4) . Removing ERCC1-XPF using FLAG beads prevented the formation of the super-shifted complexes ( Figure 3C, lane 6) .
Next, to assess whether ERCC1-XPF and RPA cooperate to remove Top1 damage in vivo, their cellular distribution was monitored using anti-XPF and anti-RPA p32 antibodies. In untreated HeLa cells, ERCC1-XPF and RPA were detected in the nucleus, but they did not form foci ( Figure 4A ). In contrast, CPT treatment resulted in distinct subnuclear focus formation by ERCC1-XPF and RPA ( Figure 4C) . Interestingly, the profile of HeLa cells treated with or without CPT ( Figure 4B and D) showed that ERCC1-XPF co-localized with RPA, suggesting that ERCC1-XPF and RPA formed a complex in vivo. In addition, similar results were obtained when ERCC1-V5-FLAG-expressing HEK293 cells were treated with CPT (Supplementary Figure S6 , available at Carcinogenesis Online).
POLD, LIG1 and FEN1 catalyze DNA synthesis
During NER (Figure 5A ), ERCC1-XPF and RPA process 5′ side incisions at DNA lesions, which is followed by the DNA repair synthesis of polymerase delta (POLD) (19, 29) . Therefore, we investigated whether POLD could catalyze DNA synthesis on a DNA template complex using a primer containing a 3′-phosphotyrosyl bond. When a normal primer containing non-phosphotyrosyl bonds was used, ERCC1-XPF nuclease activity was stimulated by RPA (Supplementary Figure S7A , available at Carcinogenesis Online, lane 3). As expected, POLD could extend DNA without ERCC1-XPF or RPA (Supplementary Figure S7A , available at Carcinogenesis Online, lane 2). However, it could extend DNA more efficiently on template/primers containing 3′-phosphotyrosyl bonds in the presence of ERCC1-XPF and RPA ( Figure 5B , lane 3) than in their absence ( Figure 5B, lane 2) . These data suggest that POLD is unable to remove 3′-phosphotyrosyl bonds from primers, but could catalyze DNA synthesis using a 3′-phosphotyrosyl bond-removed primer. In addition, DNA synthesis was required for ERCC1-XPF, RPA and POLD ( Figure 5B ). Figure S8A , available at Carcinogenesis Online) facilitates the 5′-realignment of POLD in nicked strand gaps, and LIG1 (Supplementary Figure S8B , available at Carcinogenesis Online) is required for DNA repair synthesis during NER ( Figure 5A ). Therefore, incision factors (ERCC1-XPF and RPA) and DNA repair synthesis factors (POLD, FEN1 and LIG1) were incubated with nicked substrates containing 5′-32 P-labeled 3′-phosphotyrosyl oligonucleotides under DNA repair synthesis conditions at 37°C for 90 min, and the repair of 43mer DNA fragments was assessed ( Figure 5C , lane 6). However, little repair was observed in the absence of ERCC-1-XPF ( Figure 5C, lane 7) . When FEN1 was missing from the reaction ( Figure 5C, lane 5) , slightly repaired 43mer fragments were observed because of the presence of ERCC1-XPF 3′-to-5′ nuclease activity (Supplementary Figure   Figure 3 . ERCC1-XPF and RPA bind to Tyr-nick DNA substrates and form protein-DNA complexes. The substrates were incubated with ERCC1-XPF and/or RPA at the Figure S7B , available at Carcinogenesis Online, lane 7) produced the 43mer DNA fragments expected as DNA repair products, suggesting that producing the repaired products did not require ERCC1-XPF. We next repeated the DNA repair synthesis assay with the all factors using nicked substrates containing 3′-phosphotyrosyl bonds or non-phosphotyrosyl bonds containing 3′-labeled oligonucleotides ( Figure 5C, upper panel) . Repaired products in nicked substrates containing non-phosphotyrosyl bonds were observed only when all factors were present (Supplementary Figure S7C , available at Carcinogenesis Online, lane 4); however, repairs were also made to Tyr-nick substrates ( Figure 5D,  lane 4) .
FEN1 (Supplementary
Similarly, ERCC1-XPF, RPA, POLD, FEN1 and LIG1 were incubated with nicked substrates containing 3′-phosphotyrosyl bonds in DNA repair synthesis conditions with deoxynucleoside triphosphate present (19, 30) . All factors could repair the 43mer DNA fragments in an incubation time-dependent manner (Supplementary Figure S9A , available at Carcinogenesis Online). POLD could participate in the repair reactions, whereas polymerase beta (POLB) for base excision repair (BER) and Klenow fragment E. coli DNA polymerase could not (Supplementary Figure S9B , available at Carcinogenesis Online).
Discussion
In the present study, we demonstrated that the nuclease activity of ERCC1-XPF released nucleotides containing the 3′-phosphotyrosyl bonds of unpaired 3′ tails from Y-structure substrates and the 3′-phosphotyrosyl bonds of the sticky end of 5′-overhang structures. Using DNA substrates containing 3′-phosphotyrosyl bonds in nicked DNA structures, which mimicked Top1-damaged DNA, this nuclease was unable to cleave nucleotides containing 3′-phosphotyrosyl bonds alone, but could remove them in the presence of RPA. RPA formed a complex with ERCC1-XPF and Top1-damaged DNA both in vivo and in vitro. POLD could extent a DNA strand following the removal of 3′-phosphotyrosyl bonds by RPA and ERCC1-XPF. Finally, LIG1 and FEN1 could complete the DNA repair process. Therefore, some parts of the NER machinery might play an important role in the repair of Top1 DNA damage as an alternative repair pathway.
NER factors participate in the repair of Top1-DNA lesions
ERCC1-XPF can cleave DNA substrates that form Y structures, even if their 3′ ends are modified. Therefore, it cleaves DNA strands that contain a lesion on the bubble structure formed by transcription factor IIH (TFIIH), xeroderma pigmentosum group A complementing protein (XPA) and RPA during NER. After a damage recognition step involving TFIIH, XPA is recruited to the DNA damaged region by TFIIH to release the CAK subcomplex from TFIIH and associate with RPA and the ss damaged DNA (20) . The interaction between XPA and RPA is an important step during the opening or scanning of damaged DNA that involves TFIIH, which is a DNA-dependent helicase (31) . Because RPA is a ssDNA binding protein, it is thought to be localized to the gap-ssDNA region that is produced by the excision of the damaged DNA strand (32) , where it interacts with and stimulates ERCC1-XPF on the 3′ side of the DNA junction (28) . However, the endonuclease activity of this complex is indispensable for structure-specific DNA, since ERCC-XPF alone was unable to process the 3′ end of an oligonucleotide in a nicked DNA structure.
In the current study, we demonstrated that the 3′-phosphotyrosyl bonds used to mimic Top1 damage complexes are unable to form the structure-specific DNAs that are processed by ERCC1-XPF; however, the bonds are released in the presence of RPA. Therefore, RPA may be indispensable for forming a complex with and stimulating the nuclease activity of ERCC1-XPF during the removal of Top1-damaged DNA. This is consistent with several previous observations. First, RPA was identified in a genome-wide CPT sensitivity screen (33) . Second, CPT induces phosphorylation of RPA2, which is a component of RPA (34) . Third, CPT partially produces foci of RPA for recombination repair protein Rad51 (35) , suggesting that other fractions of RPA may bind to the site of DNA damage with ERCC1-XPF.
NER can remove oligonucleotides that contain bulky DNA damage, UV-induced DNA lesions (cyclobutane pyrimidine dimers and 6-4 photoproduct) and chemical-induced cisplatin adducts that block replication and transcription (18) . NER is also likely to contribute to the repair of Top1 DNA lesions. Sastry et al. (36) suggested that human cell-free extracts could cleave Top1 DNA damage in a manner dependent on XPA, which verifies DNA lesions during NER. In addition, TC-NER-deficient Cockayne Syndrome (CSA and CSB) cells are hypersensitive to CPT (37, 38) . In contrast, yeast genetic data suggested that rad14 mutants and rad2 mutants, which correspond to XPA and XPG in humans, respectively, are not sensitive to CPT (13) . However, very little data are available regarding other NER factors (e.g. XPC, TFIIH containing xeroderma pigmentosum group B and D complementing protein) in this context. Because the excision step of NER involves at least five factors (XPA, TFIIH, ERCC1-XPF, XPG and RPA), normal NER pathways are unlikely to remove Top1 DNA lesions. The current data suggest that at least ERCC1-XPF and RPA participate in the removal of Top1-damage, and that POLD, FEN1 and LIG1, which are involved in normal NER pathways, play roles in DNA repair synthesis during the repair of Top1 DNA lesions. Therefore, the repair of Top1 DNA lesions might occur via a partial NER repair mechanism involving ERCC1-XPF, RPA, POLD, FEN1 and LIG1. Although studies of NER in human cells have mostly assessed the repair mechanism of UV-induced DNA lesions, living cells might not require all NER factors depending on the DNA lesions.
Model
The current study provides novel insights into an alternative pathway for the repair of Top1 DNA damage in human cells. When cells are treated with CPT, Top1 in the Top1-DNA cleavage complexes is degraded via a ubiquitin-26S proteasome pathway into a polypeptide with a tyrosyl residue attached to the 3′-end of nicked DNA (6, 12) . Figure 6A shows a main phosphodiesterase pathway model involving TDP1, poly(adenosine diphosphateribose) polymerase 1 (PARP1), and a BER complex including X-ray repair cross complementing 1 protein (XRCC1), polynucleotide kinase 3′-phosphatase, POLB and ligase III (LIGIII). The essential features of this model were proposed originally by Takashima (40) . After TDP1 coupling with PARP1 hydrolyzes 3′-phosphotyrosyl bonds, PARP1 recruits XRCC1 and other BER factors (POLB and LIGIII) that play roles in the repair of ss breaks. Specifically, polynucleotide kinase 3′-phosphatase hydrolyzes the resulting 3′-phosphate and phosphorylates the 5′-hydroxy end, whereas POLB and LIGIII fill and seal the DNA gap, respectively.
In Figure 6B , which shows the alternative endonuclease pathway, a model incorporating the role of ERCC1-XPF in the presence of RPA to cleave 3′-phosphotyrosyl bonds containing oligonucleotides. In this step, only ERCC1-XPF is unable to hydrolyze the phosphotyrosyl bond. Specifically, RPA is required for stimulating the nuclease activity of ERCC1-XPF in non-structure-specific DNA nicks. After removing the phosphotyrosyl oligonucleotides, NER factors (POLD, FEN1 and LIG1) fill and seal the DNA gap, similar to the mechanism of normal NER. In this step, FEN1 might play an important role in removing the 5′-hydroxyl from an end and producing a new 5′-phosphate end for the ligase reaction. This is consistent with several previous observations. For example, the FEN1 homolog yeast rad27 exhibited mild sensitivity to CPT (41) . In addition, a rad27 strain lacking the FEN1 gene and the wild-type strain had similar resistance to CPT (42) . However, a rad27 strain lacking TDP1 was not significantly more sensitive to CPT (13) , suggesting that FEN1 participates in the alternative pathway in the absence of TDP1.
Recently, it has been shown that the N-terminus domain of TDP1 directly binds PARP1, and the poly(adenosine diphosphate-ribose)ation recruits both TDP1 and XRCC1 to DNA damage sites (40) . Thus, PARP1 appears to determine whether Endonuclease pathway. ERCC1-XPF and RPA remove 3′-phosphotyrosyl bound oligonucleotides to generate a gap for POLD, FEN1 and LIG1, which are NER factors.
Top1-DNA cleavage is repaired by TDP1 or by the alternative endonuclease pathways. The Mre11-Rad50-Nbs1 complex (43), SLX4 (44) and CtIP (45, 46) , which indicate the repair of Top1-DNA cleavage complex in mammalian cells, data are not shown in this model ( Figure 6 ); however, they play an important role in the homologous recombination repair of DNA breaks induced by the damage complex (12) .
ERCC1 as a biomarker for chemotherapy
Some clinical trials reported that patients with ERCC1-negative tumors appeared to benefit from adjuvant cisplatin-based chemotherapy (47, 48) . Cisplatin is one of the most important chemotherapy agents, and it induces cytotoxic DNA adducts that are removed by NER. Therefore, tumor cells that express reduced levels of ERCC1 exhibit high cisplatin sensitivity because of reduced NER levels (49) . CPT is also one of the most commonly used and effective chemotherapeutic agents. Its cytotoxic activities in cancer cells are thought to involve the formation of DNA lesions through inhibition of Top1. Because the current data suggest that ERCC1-XPF and RPA participate in the repair of Top1 damage, low expression of these genes in tumor cells may result in high tumor sensitivity to CPT because of reduced repair function; therefore, the expression levels of these genes might be biomarkers for CPT-based chemotherapy.
Supplementary material
Supplementary Figures S1-S9 can be found at http://carcin. oxfordjournals.org/
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